Evidence map›Paper›PMID 39333520›Full record

ArticleNature communications2024

Introducing synthetic thermostable RNase inhibitors to single-cell RNA-seq.

Joyce Carol Noble, Antonio Lentini, Michael Hagemann-Jensen, Rickard Sandberg, Björn Reinius

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joyce Carol NobleDepartment of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-4450-429X
Antonio LentiniDepartment of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-1239-5495
Michael Hagemann-JensenDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-6423-8216
Rickard SandbergDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-6473-1740
Björn ReiniusDepartment of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden. bjorn.reinius@ki.se.ORCID 0000-0002-7021-5248

Funding

Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation) 2021.0142Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation) 2022.0146Svenska Sällskapet för Medicinsk Forskning (Swedish Society for Medical Research) CG-22-0260-H-02Vetenskapsrådet (Swedish Research Council) 2022-01620
6 · The paper itself

Abstract

Single-cell RNA-sequencing (scRNAseq) is revolutionizing biomedicine, propelled by advances in methodology, ease of use, and cost reduction of library preparation. Over the past decade, there have been remarkable technical improvements in most aspects of single-cell transcriptomics. Yet, little to no progress has been made in advancing RNase inhibition despite maintained RNA integrity being critical during cell collection, storage, and cDNA library generation. Here, we demonstrate that a synthetic thermostable RNase inhibitor (SEQURNA) yields single-cell libraries of equal or superior quality compared to ubiquitously used protein-based recombinant RNase inhibitors (RRIs). Importantly, the synthetic RNase inhibitor provides additional unique improvements in reproducibility and throughput, enables new experimental workflows including retained RNase inhibition throughout heat cycles, and can reduce the need for dry-ice transports. In summary, replacing RRIs represents a substantial advancement in the field of single-cell transcriptomics.

Indexed as

RibonucleasesSingle-Cell AnalysisAnimalsEnzyme InhibitorsGene LibraryHumansReproducibility of ResultsRNARNA-SeqSequence Analysis, RNASingle-Cell Gene Expression AnalysisEnzyme InhibitorsRibonucleasesRNA

Identifiers

PMID39333520
PMCPMC11437267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.